GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
GT Biopharma, Inc. (GTBP), a Delaware corporation operating as a fully remote company since July 1, 2024, filed this Current Report on Form 8-K dated May 12, 2025. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
The Company executed a Securities Purchase Agreement for a private offering with the following terms:
- Aggregate Purchase Price: $5,450,000.00
- Securities Issued: Up to 6,056 shares of Series L 10% Convertible Preferred Stock with an aggregate stated value of $6,055,555.56.
- Warrants Issued: Common Warrants to purchase 100% of the shares issuable upon conversion of the Preferred Stock, plus Vesting Warrants tied to the exercise of Greenshoe Rights.
- Greenshoe Option: Purchasers may elect to purchase additional Preferred Stock with an aggregate stated value of up to $22,000,000 for a purchase price of $19,800,000.
- Conversion Price: Initial conversion price of $2.043 per share.
- Dividend Rate: 10% per annum cumulative until May 11, 2026, increasing to 12% per annum thereafter.
- Price Protection: Full ratchet anti-dilution protection with a floor price of $0.454 per share.
Note: This filing does not provide revenue, profit, cash flow, or general liquidity metrics for the Company's operations.
Material Changes and Agreements
The filing details several material agreements entered into on May 12, 2025:
- Registration Rights: The Company agreed to file a registration statement within 30 days of closing, effective within 90 days. Failure to meet these deadlines incurs liquidated damages of 1.5% of the subscription amount, plus interest at the prime rate plus 12% if unpaid within 7 days.
- Voting Agreement: All officers and directors agreed to vote in favor of stockholder approval required for the issuance of more than 19.99% of outstanding common stock.
- Lock-Up Agreement: Officers and directors are restricted from selling securities for 30 days after the later of the Registration Statement Effective Date or the date Shareholder Approval is obtained.
Outlook, Risks, and Contingencies
The transaction is contingent upon obtaining stockholder approval for the issuance of shares exceeding 19.99% of the outstanding common stock. The Company must hold a stockholder meeting at the earliest practical date to secure this approval. The Preferred Stock includes redemption rights upon certain triggering events and carries a significant dividend obligation that increases after May 2026. The full ratchet provision poses a risk of significant dilution to existing common shareholders in the event of future down-rounds.
Key Facts for Investor Verification
- Verify the status of the required stockholder meeting and approval for the issuance of >19.99% of common stock.
- Confirm the Company's ability to meet the 30-day filing and 90-day effectiveness deadlines for the registration statement to avoid liquidated damages.
- Assess the impact of the 10% (rising to 12%) cumulative dividend obligation on the Company's future cash flow and liquidity.
- Review the full ratchet anti-dilution terms and the $0.454 floor price to understand potential dilution scenarios.
- Monitor the exercise of the $19.8 million Greenshoe option by purchasers.